Biological E

The tech transfer will be completed by 2025 and the vaccine will be manufactured for India and international markets by Biological E

Japanese drug firm Takeda on Tuesday said it has tied up with Hyderabad-based firm Biological E Ltd to manufacture its dengue vaccine. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organisation to achieve zero case-fatality rate due to dengue by 2030, the company said in a statement. The partnership will substantially enhance manufacturing capabilities to ensure a sustainable global supply of the vaccine, it added. Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 million doses annually within the decade, it said. "We are proud to announce a strategic manufacturing partnership with Biological E Ltd which has deep expertise in vaccine manufacturing and longstanding support of public health programmes around the world," Takeda President of the Global Vaccine ...

XBB 1.5 is a sub-variant of Omicron, and a sub-linear of XBB variant. It is a recombinant of the two BA.2 sublineages, and carries a mutation of the spike protein (F486P)

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin. Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government. In March '22, Biological E successfully supplied 10 crore doses to the government. "Currently, we have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly," Paradkar

Montreal deal also aims to provide critical financing to developing world; draft calls for raising $200 billion by 2030 for biodiversity, with a plan that could provide another $500 billion

iNCOVACC first intranasal Covid shot to receive approval for primary 2-dose schedule, heterologous booster us

With a wealth of Rs 8,700 crore, Mahima Datla and family, promoter of Biological E Ltd is the richest woman in Andhra Pradesh and Telangana to feature in the IIFL Wealth Hurun India Rich List 2022. She is in the 10th position when it comes to overall list of both the states. Krishna Ella, chairman and managing drector of Bharat Biotech International Limited and his family for the first time figured in the list with Rs 4,700 crore wealth in 18th position. Gautam Adani and family stood first in the chart of all India with Rs 10,94,400 crore wealth followed by Mukesh Ambani & family with Rs 7,94,700 crore and Cyrus S Poonawalla and family (Serum Institute of India) with Rs 2,05,400 crore. Hurun Report India and IIFL Wealth unveiled the 2022 edition of 'IIFL Wealth Hurun India Rich List 2022' - a compilation of the richest individuals in India having a wealth of Rs 1,000 crore or more on Wednesday. Murali Divi and family promoters of Divi's Laboratories was on the top of th

Biological E Limited on Thursday announced that the Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) reviewed and approved the Phase 3 infants' clinical trial data and recommended for manufacture its 14-valent paediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) against S pneumonia infection, in single-dose and multi-dose presentations. A press release from the city-based vaccine maker said the PCV14 can be administered to infants at six, 10 and 14 weeks of age. Streptococcus pneumoniae infection continues to be a leading cause of child mortality under 5 years of age in India and in developing countries. With the PCV14 vaccine, BE hopes to contribute to the prevention of invasive pneumococcal disease and protect millions of lives globally. The safety analysis of the vaccine revealed that all the adverse events were mild to moderate in their intensity and with no grade-3 & 4 events reported. Mahima Datla, Managing ..

Among the companies that are working with ICMR are Serum Institute of India (SII), Reliance Life Sciences, Dr Reddy's Laboratories, and Biological E

Health ministry nod to the Biological E vaccine as 3rd dose after Covishield or Covaxin, CoWIN to be updated within a week

: Vaccine maker Biological E on Thursday announced its expansion plans for investment of over Rs 1,800 crore, which will generate employment of more than 2500 people in their three facilities in Genome Valley here. According to a press release issued by the state government, the expansion is primarily targeted to ramp up the manufacturing of vaccines along with generic Injectables and R&D. The announcement was made after IT and Industries Minister KT Rama Rao's meeting with leadership of Biological E Mahima Datla, Managing Director. Rama Rao said, I'm delighted to announce the expansion plans of Biological E in Genome Valley. Hyderabad is already known as the vaccine Capital of the World and this expansion further accelerates our strength to serve the world with live saving vaccines. The investment from Biological E will enhance the capacity by five billion doses increasing the cumulative capacity to about 14 billion doses each year. Mahima Datla, Managing Director of ...

Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine. "Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing," the US embassy in India said in a tweet on Wednesday. India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years. The Drugs Controller General of India (DCGI) recently approved Corbevax as a precaution dose for those aged 18 and above.

End user would now need to pay Rs 400 per jab including the administration charge to get the shot at a private vaccination centre; move aimed at benefiting children

The privately held company has a turnover of about Rs 1,000 crore, of which close to 70-80 per cent come from the vaccines business now

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the commercial growth engines

At present, the firm has a capacity to make 1.5-2 billion Covid vaccines and 600 million non-Covid vaccines per annum.

DCGI has granted emergency use authorisation for Biological E's Covid-19 vaccine Corbevax and Bharat Biotech's Covaxin

WHO and partners to work with Indian govt and the firm to develop roadmap and put in place training and support for Biological E to start producing mRNA vaccines at the earliest

At present, India has no Covid-19 vaccine made on mRNA platform

Plans to test vaccine on six-month old infants; seeks EUA for 5- to 12-yr-old children